[Structure Catalyst] Building a Korean Mega-GPO Platform: A Roll-up Strategy for the Fragmented Medical Device Distribution Market – Part 1

by

Executive Summary

Changes in the Regulatory Landscape Following the December 2025 Amendment to the Medical Device Act and Opportunities for Consolidating Institutional, Small-scale, and SME Distributors

  • The amendment to the Medical Device Act (which completely bans transactions with affiliated distributors(*)), passed by the National Assembly in December 2025, carries the same disruptive impact as the past amendment to the Pharmaceutical Affairs Act (regulation of pharmaceutical wholesalers) that birthed the pharmaceutical mega-platform “Geo-Young.”
  • This serves as a perfect entry barrier and momentum to dismantle the fragmented distributor market, which had proliferated for the purpose of internalizing profits (collecting toll fees) for hospitals and foundations.
  • Therefore, the objective is to absorb the forced sale targets that will flood the market within the grace period (2 years, until the end of 2027), inject capital and IT systems, and roll up these shadow broker-type distributors into a transparent, irreplaceable tech-based GPO platform to achieve a successful exit.
  • (*) Group Purchasing Organization (GPO)

Key Investment Highlights

  • Massive Influx of Forced Sellers Driven by a Strong Regulatory Catalyst
    • With the newly established comprehensive criteria for determining affiliated parties and punitive sanctions (imprisonment and fines), formal regulatory evasion through ownership dilution or indirect ownership structures is fundamentally blocked.
    • Before the grace period ends at the end of 2027, a structural environment is created where numerous captive distributors owned by foundations and hospital directors—who relied solely on supply rights without independent logistics fundamentals—will be forced onto the M&A market en masse to survive.
  • Potential for Multiple Arbitrage via Roll-up
    • Bargain Purchasing and Cost Efficiency Potential: Regulatory-evading, small-scale distributors can be acquired at low multiples.
    • Integrating the acquired companies into the central ERP and WMS (Warehouse Management System) of a pre-established anchor company will instantly eliminate unnecessary and redundant SG&A expenses (such as labor costs), enabling an increase in operating profit.
    • Value Enhancement through Business Model Pivoting: Drastically lowering the cost of goods sold (COGS) through logistics cost reduction and expanded buying power resulting from distribution network consolidation.
    • Furthermore, by moving beyond a distribution margin (spread) model constrained by government price caps, and improving the corporate constitution to a SaaS and fee-based model—such as operating room surgical kitting and clinical data-driven consulting—the strategy secures an IT/BPO platform-level premium (double digit x+) upon exit.

Stable Cash Flow

  • Downside Protection and Structural Growth: The domestic medical device (including therapeutic materials) market grew at a high CAGR of 8.8%, from approximately KRW 7.5 trillion in 2020 to KRW 10.5 trillion in 2024; this is due to its strong downside protection that remains unaffected by economic fluctuations, driven by an aging population and an increase in chronic diseases (Recession-proof).
  • Maximizing Profitability through Non-Reimbursable Upside: By expanding the portfolio to include the aesthetics (dermatology and plastic surgery) and large capital goods markets, which are not subject to national health insurance price controls, the structure can drive simultaneous growth in top-line volume (Q) through roll-ups and unit price/margins (P).

Execution Strategy

  • Execute a bolt-on strategy after acquiring a prime anchor company centered in the Seoul metropolitan area and specific medical departments.
  • Phase 1 (Platform Acquisition): Establish a Control Tower by prioritizing the acquisition of a prime anchor target (KRW 100+ billion in revenue) that is eligible for a buyout, not subordinated to a specific foundation, and has internalized IT logistics infrastructure such as a metropolitan hub warehouse, proprietary WMS, and EDI (Electronic Data Interchange).
  • Phase 2 (Bolt-on & Lock-in): Acquire the influx of small-scale captive distributors (KRW 30 billion to 100 billion in revenue) in alignment with the grace period timeline.
  • Simultaneously, provide VMI (Vendor-Managed Inventory) and surgery-specific material kitting services to synchronize the client hospitals’ IT networks with our system, completing a digital lock-in that competitors cannot easily replicate.
  • Phase 3 (Exit Story): Armed with a transparent compliance SCM infrastructure, maximize exit returns by selling to domestic large Strategic Investors (SIs/conglomerates) aiming to build healthcare clinical big data pipelines, or to global mega GPOs and large Financial Investors (FIs) seeking an Asian hub.

Market Dynamics & Regulatory Landscape

Pharmaceutical Market vs. Medical Device/Therapeutic Materials Market

Comparison of Definitions and Characteristics: Pharmaceuticals vs. Medical Devices & Therapeutic Materials

  • Although pharmaceuticals and medical devices/therapeutic materials seem to share a similar medical distribution ecosystem, they differ in the characteristics of handled items, applied regulations, and profit structures.
  • Pharmaceuticals: Chemical and biological substances intended for the diagnosis, treatment, or prevention of disease, subject to strict regulation under the Pharmaceutical Affairs Act.
    • Characteristics: Ingredients and specifications are highly standardized, making logistics handling relatively less difficult; achieving economies of scale through a nationwide, large-scale logistics network is the core competitive advantage.
    • Profit Structure: Structural generation of distribution margins is limited due to the application of the “Actual Transaction Price Reimbursement System.”
  • Medical Devices & Therapeutic Materials (Consumables): Encompasses instruments and materials such as surgical consumables (gauze, sutures), artificial joints, catheters, and diagnostic equipment, regulated by the Medical Device Act.
    • Characteristics: Items (SKUs) are highly fragmented into tens of thousands of types, necessitating advanced hospital-customized inventory management (VMI), such as deliveries tailored to surgical schedules.
    • Profit Structure: Subject to the “National Health Insurance Price Cap,” allowing for the collection of a margin (Spread) through low-cost purchases from manufacturers and high-priced supplies to hospitals.

※ Reference: Health Insurance Price Cap vs. Actual Transaction Price Reimbursement System

  • Health Insurance Price Cap
    • Concept: The maximum price the National Health Insurance Service (NHIS) can pay a hospital for a specific therapeutic material (or drug), as determined by the Ministry of Health and Welfare’s notified “List of Reimbursable/Non-Reimbursable Therapeutic Materials and Upper Limit Prices.”
    • Purpose: Serves as a “safety mechanism” to prevent infinite leakage of health insurance finances.
  • Actual Transaction Price Reimbursement System
    • Concept: A system where hospitals can only claim and be reimbursed by the NHIS for the exact price they actually paid (discounted price) when purchasing goods from a manufacturer or distributor.
    • Background of Introduction: A regulation created in 1999 to prevent practices where hospitals pressured manufacturers to buy a KRW 10,000 item for KRW 6,000, then billed the NHIS for KRW 10,000 (the price cap) to pocket a KRW 4,000 margin (back margin/rebate).
    • Mechanism (Example): If a hospital negotiates and buys an item with a price cap of KRW 10,000 at a discounted price of KRW 6,000, it claims and receives KRW 6,000 from the Health Insurance Review and Assessment Service (HIRA). Thus, from the hospital’s perspective, “purchase margin (Spread)” is fundamentally blocked.

The Birth of Distributors as a Bypass to Secure Spread

  • Due to the Actual Transaction Price Reimbursement System, even if a hospital buys items cheaply, HIRA only reimburses the discounted amount, eliminating the economic incentive for hospitals to negotiate prices directly with manufacturers. Instead, to bypass this, distributors were established to act as intermediaries between hospitals and manufacturers as follows.
    • Manufacturer → Distributor: The distributor leverages bulk purchasing (Volume) to negotiate with the manufacturer and buy items at a price lower than the cap (e.g., buying a KRW 10,000 medical device/therapeutic material for KRW 8,000).
    • Distributor → Hospital: The distributor supplies this to the hospital for KRW 10,000 (the price cap).
    • Hospital → HIRA: The hospital claims KRW 10,000 from HIRA based on the tax invoice (receipt of actual transaction price) from the distributor and is fully reimbursed.
  • In conclusion, the KRW 2,000 margin that the hospital could not directly collect due to the actual transaction price reimbursement system is converted into the distributor’s “legal distribution spread.”

Direct Wholesalers and Distributors (GPOs): Intermediaries in the Hospital Distribution Value Chain

  • The intermediary distributors connecting the demand side (hospitals with strong bargaining power) and the structurally inferior multiple manufacturers are classified into direct wholesalers (for pharmaceuticals) and distributors/GPOs (for medical devices/therapeutic materials), with roles as follows.
  • Pharmaceutical Distribution: Direct Wholesalers (or Ethical Wholesalers)
    • Refers to distributors where affiliated parties, such as large hospital founders or foundation chairmen, historically held shares and monopolized the supply of specialized prescription drugs (ETC, Ethical Therapeutic Class) required by their own hospitals.
    • Essentially, like medical device distributors, they used their dominant position to secure margins from pharmaceutical companies and acted as a channel for rebates; however, following the amendment to the Pharmaceutical Affairs Act in 2011 and its enforcement in 2012, the dominance of direct wholesalers owned by medical institution founders was dismantled, entirely reorganizing the distribution ecosystem around independent mega vendors.
  • Medical Device/Therapeutic Material Distribution: Distributors (Group Purchasing Organizations, GPO)
    • The core players currently targeted for deals, referring to distributors that supply the medical devices and therapeutic materials needed by hospitals and foundations.
    • Currently, with the exception of a few, most domestic firms lack the logistics innovation or cost-reduction functions provided by advanced GPOs, and instead leverage hospital supply rights to internalize intermediate margins from medical device/therapeutic material manufacturers under the guise of delayed payments, excessive supply price discounts, consignment supply (temporary supply without contracts), and various fees.

Medical Distribution Market Reorganization Process According to Domestic Regulatory Timeline

  • Stricter government regulations are expected to act as a core catalyst for dismantling the abnormal distribution structure based on affiliated parties and creating opportunities for scaling up led by external capital (such as private equity funds).
  • [Phase 1 – Pre-2011] Before the Amendment of the Pharmaceutical Affairs Act
    • A period where both pharmaceutical and medical device distributions were monopolized by direct wholesalers and distributors tied to hospitals through special relationships, cementing the market structure.
    • Side effects existed, such as financial leakage from health insurance and unfair practices, including excessive price squeezing on manufacturers and toll collection to maximize ancillary profits for hospitals and foundations.
  • [Phase 2 – 2012~2025] Post-Pharmaceutical Affairs Act Amendment ~ Pre-Medical Device Act Amendment
    • With the enforcement of the revised Article 47 of the Pharmaceutical Affairs Act in 2012, pharmaceutical transactions with affiliated direct wholesalers were completely banned.
    • Consequently, independent mega-vendors like Geo-Young emerged by preemptively bolting on the direct wholesalers that flooded the market, completing the modernization and consolidation of distribution.
    • Medical Device & Therapeutic Material Market: Left in a regulatory blind spot due to complex interests, distributors instead further sophisticated their methods of internalizing intermediate margins, such as consignment supply and fee collection.
  • [Phase 3 – Dec 2025~] Post-Medical Device Act Amendment
    • The amendment to the Medical Device Act, which bans transactions with affiliated distributors at the same level as pharmaceuticals, passed the National Assembly plenary session.
    • By the end of the grace period in 2027, existing captive distributors owned by hospitals, foundations, and affiliated parties will face forced sale pressures, and the valuation re-rating and roll-up opportunities that previously occurred in the pharmaceutical wholesale market are expected to be replicated in the current medical device distributor market.

Macro Market Environment and Structural Growth of the Medical Distribution Market

  • The medical distribution market possesses downside rigidity unaffected by economic cycles while simultaneously securing strong structural demand growth momentum across all age groups.
  • Recession-proof Characteristics: Medical devices and therapeutic materials are essential goods directly linked to maintaining life and health; their demand has low price elasticity even during macroeconomic slowdowns or interest rate hike periods, enabling stable cash flow generation.
  • Explosion in Demand for Essential Medical Care Due to Super-Aging Population: The rapid aging of the demographic structure is causing a continuous increase in the number of patients with chronic diseases and those requiring severe/surgical care.
    • This guarantees the structural volume (Q) growth of high-unit-price, high-value-added therapeutic materials such as orthopedic artificial joints, cardiovascular stents, and catheters.
  • Surge in Demand for Aesthetics and Non-Reimbursable Care Among Younger Generations: Beyond traditional patient groups, demand for aesthetic medical devices (laser equipment, fillers, toxins, etc.) and related consumables for dermatology, plastic surgery, and anti-aging purposes is growing explosively, primarily driven by younger demographics like the MZ generation.
    • This sector has a high proportion of non-reimbursable areas free from health insurance price controls, acting as a strong alpha factor that drives margin (P) expansion and explosive top-line growth for distribution companies.

※ Reference: December 2025 Amendment to the Medical Device Act

  • Core Content and Background of the Amendment
    • Core Content: Completely bans direct and indirect supply transactions of medical devices between a medical institution and a distributor (medical device wholesaler) operated by the founder of the medical institution (hospital/foundation) or an affiliated party (Passed National Assembly plenary session on Dec 2, 2025).
    • Legislative Background: While pharmaceuticals were previously restricted from affiliated transactions under the Pharmaceutical Affairs Act, medical devices remained in a regulatory blind spot. As distributors were effectively utilized as legal rebate channels (excessive discounts, toll fees, etc.) for hospitals, this amendment aims to block this at the source.
    • Timeline: Existing transaction relationships must be dissolved by the end of the 2-year grace period (end of 2027).
  • Criteria for Determining Affiliated Parties and Sanctions
    • Judgment Criteria: Introduces comprehensive criteria including ① Relatives within the second degree of kinship, ② Owners exceeding 50% equity, and ③ Persons exercising substantial or dominant influence over business operations.
    • Sanction Level: Violations are subject to criminal penalties such as imprisonment for up to 1 year or fines up to KRW 10 million, as well as administrative dispositions.
    • (However, this applies only to medical device distributors/lessors; direct supply by manufacturers is not subject to regulation).
  • Restriction of Existing Unfair Practices and Market Transparency Measures
    • The following clauses were newly established to block unfair practices by existing distributors (e.g., chronic payment delays, consignment without contracts).
    • Mandatory drafting of contracts including essential terms during transactions.
    • Mandatory payment of prices within 6 months from the date of receipt.
    • Imposition of up to 20% annual delay interest for late payments.

Deal Implication: Prospects of M&A Market Influx According to Response Strategies

  • Impossibility of Evasion via Equity Splitting: Even if the equity of oneself or affiliated parties is simply lowered to below 50%, legal risks remain very high due to the substantial dominance clause.
  • Realistic Options for Hospitals (Sellers): To completely resolve legal risks, the only viable methods are essentially ① closing the distributor business, ② abandoning supply to their own hospital, or ③ fully selling management rights to a third party with absolutely no special relationship.
  • Therefore, a structural environment is established where a massive number of foundation and small-to-medium distributor assets, seeking to exit by securing a management premium within the grace period, will inevitably flood the market.

Comparison of Distribution Structure and Margin Mechanisms: Pharmaceuticals vs. Medical Devices/Therapeutic Materials

  • The pharmaceutical distribution market demonstrates the future direction that the medical device and therapeutic materials market will inevitably take following the introduction of this regulation.
  • Although both markets share hospitals as their final demand source, there are differences in the fundamental mechanisms for generating profit and the past regulatory environments, as shown below.
  • (Regulatory Lag and Differences in Distribution Ecosystems) The biggest difference is the timing of regulations on captive sales utilizing affiliated parties.
  • To prevent the leakage of national health insurance finances, the pharmaceutical distribution market already amended the Pharmaceutical Affairs Act in 2012, completely banning transactions with affiliated parties, such as hospital-owned wholesalers.
  • As a result, former hospital-direct wholesalers were forced onto the market and were successfully reorganized into a market centered around independent mega-vendors like Geo-Young, who preemptively rolled them up.
  • On the other hand, medical device distribution has lingered in a regulatory blind spot for a long time due to the massive number of items (SKUs) numbering in the tens of thousands and its complexity; as a result, the ecosystem where captive distributors owned by hospitals or foundations dominate the market has been maintained.
  • (Item Characteristics and the Difficulty of Logistics Advancement) Regarding the physical nature of the handled goods, pharmaceuticals are highly standardized in their ingredients and specifications, making the achievement of economies of scale through nationwide, large-scale logistics processing (Volume Game) an absolute competitive advantage.
  • Conversely, medical devices and therapeutic materials not only have a vast array of types, such as artificial joints and catheters, but also require advanced service capabilities, such as deliveries tailored to individual surgical schedules and vendor-managed inventory (VMI) linked to hospital information systems (HIS), rather than simple delivery.
  • (Differences in Profit Structure and Margin Internalization) Pharmaceuticals are subject to the “Actual Transaction Price Reimbursement System,” meaning that even if a hospital purchases drugs at a low price from a pharmaceutical company or wholesaler, it must report the exact purchase cost when claiming health insurance.
  • In other words, the margin that the hospital can take during the distribution process is legally blocked.
  • In contrast, the medical device and therapeutic materials market is subject to the health insurance price cap system.
  • Distributors use their guaranteed supply destination (affiliated hospital) as leverage to exert bargaining power over suppliers like manufacturers, purchasing goods at prices much lower than the price cap, and then supplying them to the hospital at or near the price cap.
  • The trading profit (Spread) generated here is wholly retained as the profit of the captive distributor, ultimately reverting as revenue to the affiliated party, such as the hospital or foundation family.
  • (Absence of Cost Compensation and Rationalization of Shifting Responsibility) Under the current Medical Service Act, the management costs of pharmaceuticals are recognized as a separate medical fee for hospitals. However, despite the massive management costs incurred for medical devices and therapeutic materials, such as operating room setups, these are not recognized as legal medical fees.
  • Due to this institutional loophole, hospitals shift the management responsibility to distributors under the pretext of cost compensation. Distributors, in turn, shift all risks and costs to the end-tier manufacturers in a relay through unfair practices (consignment, toll fees, delayed payments, etc.) to secure their distribution margin.
  • ☞ As the past pharmaceutical market has shown, the amendment to the Medical Device Act is expected to negatively impact the sustainability of this captive-based profit internalization model.
  • Companies that rely solely on toll fees under the guise of special relationships, without actual logistics or inventory management capabilities, can no longer survive independently, creating a roll-up opportunity suitable for capital equipped with advanced logistics systems.

[Comparison between Pharmaceuticals and Medical Devices/Therapeutic Materials] The following table:

  • Category | Pharmaceuticals | Medical Devices & Therapeutic Materials
  • Restriction on Direct Transactions / Equity Ownership in Distributors by Medical Institution Founders(*) | Banned (Implemented with ’12 Pharmaceutical Affairs Act Revision) | Imminent Regulation (Dec ’25 Medical Device Act Revision, Effective end of ’27)
  • Item and Logistics Characteristics | Item standardization, easy mass logistics | Tens of thousands of SKUs, requires integration with hospital IT networks and complex VMI
  • Recognition of Management Cost Fees | Recognized (O) (Separately compensated under Medical Service Act) | Not Recognized (X) (Justification for passing costs to distributors/manufacturers)
  • Profit Structure | Actual Transaction Price Reimbursement System (No hospital margin) | Price Cap System Applied (Margin generated from low purchase-high supply price difference)
  • Core Profit Mechanism | Economies of scale through bulk purchasing and delivery | Profit internalization based on affiliated relationships
  • Distribution Ecosystem Composition | Centered around independent large vendors (e.g., Geo-Young) | Centered around Captive distributors owned by hospitals/foundations (*) Medical institution founders (hospital directors, foundations, etc.) and affiliated parties.

Structural Contradictions in the Existing Distributor Market

  • The distribution ecosystem for medical devices and therapeutic materials has a contradictory structure where hospitals, the final demand source with overwhelming bargaining power, shift all risks and costs within the supply chain to end-tier manufacturers via captive distributors based on special relationships. At the root of this contradiction lies an imbalance in the Medical Service Act and the health insurance system.
  • (Recognition of Management Costs: Pharmaceuticals vs. Medical Devices/Therapeutic Materials) Under the current Medical Service Act, for pharmaceuticals used in hospitals, the costs associated with purchasing, quality, and inventory management are recognized as separate management costs.
  • The fact that management costs are recognized as fees means that the hospital receives legal operating revenue (management fee) from the state for the act of storing and managing therapeutic materials.
  • This causes the practice of hospitals passing costs onto distributors—justified by the absence of fees—to lose its economic validity, and provides an opportunity for hospitals to take direct legal responsibility and initiative in inventory management using transparent financial resources.
  • Consequently, hospitals use the secured management fees to transparently outsource management tasks to specialized GPOs equipped with advanced logistics systems.
  • Conversely, for medical devices and therapeutic materials categorized into tens of thousands of SKUs (like surgical sutures, gauze, artificial joints, catheters, etc.), despite incurring massive inventory management costs (operating room setups, storage, etc.), these are currently not recognized as medical fees.
  • (Relay Shifting of Costs) Instead of bearing the legally uncompensated material management costs themselves, hospitals pass them through to the intermediate distribution network, the distributors.
  • Distributors then pass these onto the end-tier medical device and therapeutic material manufacturers, causing distortions across the entire distribution ecosystem.

Examples of Major Unfair Trade Practices by Distributors

  • Distributors maximize distribution margins through the following unfair practices, which are key factors undermining the fundamentals of manufacturers.
  • Chronic Delays in Payment for Goods (Working Capital Pressure): When distributors sign supply contracts with medical device companies, they generally set long-term payment deadlines of 6 months to over 1 year without providing guarantees or collateral.
  • In many cases, even these deadlines are not met, leading to severe working capital crunches for small-scale manufacturers even after they have delivered the goods.
  • Excessive Supply Price Discounts and Forced Bleeding Competition: To win a hospital’s supply contract, the distributor unilaterally passes the discount rate (cost) generated during the bidding process onto the manufacturer supplying the goods, forcibly lowering the purchase unit price.
  • Unjustified Multiple Fee Charges (Toll Fees): Although the actual tasks required for supply (sales, delivery, inventory management) are entirely performed by the manufacturer’s sales representatives, the distributor collects various fees in the middle under names such as information usage fees, logistics fees, and tax invoice issuance fees.
  • Rampant Practices of Unauthorized Supply and Consignment Without Contracts: For expensive implants or multi-variety surgical instruments, goods are first supplied to the hospital’s operating room or warehouse without formal purchase order contracts (‘consignment’), and payment is calculated at the point of actual surgical use, thereby infinitely extending the payment date.
  • If consigned products exceed their expiration dates, the cost of disposing of them and replacing them with new products free of charge is also passed on to the manufacturer.
  • Unilateral Shifting of Various Incidental Responsibilities: The responsibility for mismanagement, such as discrepancies in supplied quantities, loss, or damage occurring within the hospital, is forced onto the medical device company’s sales representative rather than the distributor.

[Types of Major Unfair Practices by Distributors] The following table:

  • Type of Unfair Practice | Detailed Content | Damage to Manufacturer & Negative Impact on Industry
  • Chronic Payment Delays | Delays in payment for 6 months to over 1 year without guarantee/collateral | Induces working capital crunches and bankruptcies of profitable small medical device manufacturers
  • Excessive Supply Price Discounts | Unilateral transfer of discount rates and costs incurred during hospital bidding to the manufacturer | Damages the manufacturer’s profit margins and destroys R&D investment capacity
  • Collection of Multiple Fees | Charging unjustified fees such as information usage fees, logistics fees, tax invoice issuance fees, etc. | Abnormal collection of toll fees without actual value creation
  • Abuse of Consignment (Temporary Supply) | Forcing products to be pre-delivered to operating rooms/warehouses without formal contracts (Consignment) | Passing on the risks of expired inventory (disposal), loss, and sunk costs
  • Shifting Incidental Responsibilities | Transferring blame to sales reps when issues arise due to quantity discrepancies or poor management | Shifting the distributor’s lack of logistics/inventory management capabilities onto the manufacturer
  • ☞ Currently, small-to-medium and foundation-affiliated distributors fail to generate the practical added value that advanced GPOs should possess, such as demand forecasting, VMI (Vendor-Managed Inventory), and logistics standardization.
  • In particular, for distributors reliant solely on blind spots and affiliated relationships, cutting this connection makes their independent survival impossible, making a massive influx of M&A targets inevitable.

Analysis of the Medical Device Act Amendment and Market Reorganization Prospects

  • Core Content and Legislative Background
  • The essence of the Medical Device Act amendment, passed by the National Assembly plenary session in Dec 2025, is the prohibition of transactions with distributors operated by medical institution founders and affiliated parties.
  • Applying the same affiliated party criteria as the Pharmaceutical Affairs Act, medical device sales companies operated by relatives within the second degree of kinship of the hospital director, or by executives and controlling shareholders of the medical institution, are expected to effectively face exit procedures.
  • In the past, a significant number of medium-to-large hospitals and foundations established distributors under family names, etc., to exclusively supply medical devices and consumables to their own hospitals. In this process, they demanded excessive discount rates from manufacturers or collected toll fees (Margins) through paper-only consignments (temporary supplies), effectively utilizing them as legal rebate channels.
  • Consequently, this shifted the burden onto sellers and generated a structural contradiction where health insurance finances translated into ancillary profits for hospitals.
  • Regulatory Lag: Reasons for the Delay in the Medical Device Act (Medical Devices/Therapeutic Materials) Amendment Compared to the Pharmaceutical Affairs Act (Pharmaceuticals)
  • Because pharmaceuticals are directly linked to human lives and account for an absolute proportion of health insurance finances, the government proactively and completely blocked pharmaceutical transactions with direct wholesalers (affiliated parties) through the 2011 Pharmaceutical Affairs Act amendment (enforced in June 2012).
  • In contrast, medical devices and therapeutic materials have a vastly larger number of items (SKUs) compared to pharmaceuticals, and their distribution structures, including repairs and maintenance, are fragmented, leaving them relatively in a regulatory blind spot.
  • While pharmaceutical distribution became transparent, a social consensus formed that the unfair practices of medical device distributors had crossed a critical threshold, leading to this legislation.

Geo-Young: Case Study of M&A among Pharmaceutical Distributors Following the Pharmaceutical Affairs Act Amendment

  • Large-scale M&As in the pharmaceutical distribution market occurred around the enforcement of the past Pharmaceutical Affairs Act amendment in June 2012.
  • The strengthening of regulations caused fragmented small-scale and direct wholesalers to lose their self-sustainability, providing bolt-on opportunities for capitalized players.
  • Geo-Young Case
  • Received investments from Goldman Sachs PIA (KRW 40 billion in ’09) and Anchor Equity Partners (KRW 155 billion in ’13).
  • Aggressively bolted on local small wholesalers that flooded the market as forced sales due to an inability to cope with regulations, as well as Carecamp (in ’14, then a subsidiary of Samsung C&T), growing into the overwhelming #1 platform with a national network.
  • Maximized bargaining power by achieving economies of scale, passed through Blackstone (KRW 1.1 trillion in ’19), and was sold to MBK Partners in ’24 at an enterprise value of approximately KRW 2 trillion.
  • ☞ The amendment to the Medical Device Act is similar to the trend that occurred in the pharmaceutical wholesale market in the past.
  • If foundation and affiliated-party-centric distributors are purchased and rolled up at reasonable valuations by the end of the grace period, it is deemed possible to build a mega distribution platform like a second Geo-Young.

Market Size & Fragmentation

  • Market Size for Medical Device and Therapeutic Material Distribution
  • The medical device and therapeutic material distribution market forms a massive market size sufficient to deploy a fund as a single sector.
  • Medical Device Market Size: According to the Korea Medical Devices Industrial Coop. Association (KMDIA) and industry estimates, the total domestic medical device market size (production + imports – exports) as of 2024 is estimated at around KRW 10.5 trillion to 11 trillion, recording solid structural growth (CAGR) of 7-8% annually.
  • Therapeutic Material Market Size: Currently, the core domain of distributors is the reimbursable therapeutic material market covered by health insurance. Based on billing statistics from HIRA, the billed amount for therapeutic materials grew rapidly at an annual average of 9.4%, from roughly KRW 4.6993 trillion in ’21 to KRW 6.1580 trillion in ’24.
  • TAM (Total Addressable Market) Upside through Expansion into Non-reimbursable and Capital Goods: Based on the reimbursable market above (KRW 6 trillion), if we include non-reimbursable consumables excluded from health insurance statistics (e.g., implants, aesthetic materials for dermatology/plastic surgery) and large medical diagnostic equipment (capital goods) distribution markets, the practical TAM penetrable by our integrated platform is estimated to be at least KRW 8 trillion to over KRW 10 trillion.
  • This is judged to exceed the size of the waste management market, where domestic PEFs realized massive profits as their primary roll-up market in the past.
  • Extreme Market Fragmentation and Market Shares of Key Players
  • Despite the vast TAM described above, the current medical device distribution market is a typically fragmented market entirely lacking a national integrated platform that has achieved economies of scale, unlike Geo-Young in the past pharmaceutical market.
  • Proliferation of hundreds of small players: There are hundreds of companies nationwide registered as medical device sales businesses with the Ministry of Food and Drug Safety, and the companies effectively driving distributor supply to hospitals are also divided into the dozens.
  • This is the result of individual large hospital directors or medical foundations establishing affiliated distributors under a regulatory blind spot.
  • Low Market Share of Top-tier Companies: Within the market, some top distributors exist, such as EZMedicom (mainly for national/public hospitals like Seoul National Univ. Hospital), Opera Salutaris (foundation-affiliated, like Catholic St. Mary’s Hospital), and Carecamp (Geo-Young, etc.).
  • However, the combined revenue of these top 3 to 5 companies accounts for a combined market share of only around 10% within the total TAM.
  • In other words, the remaining 90% of the market is fragmented into captive distributors generating tens to hundreds of billions of won, relying exclusively on closed affiliated relationships with individual hospitals.
  • This means that if capital possessing strong financial power and the capability to transplant advanced IT and logistics systems enters and executes aggressive roll-ups, there is a backdrop to absorb market share without resistance in a short period.

Analysis of Potential Bolt-on Targets (Target Pool) and Selection Criteria

  • As the Medical Device Act amendment leads to a massive influx of forced sellers by the end of the grace period in late 2027, an M&A pipeline must be built by classifying the target pool into two stages as follows.
  • Tier 1: The Backbone of the Platform, Anchor Targets
  • Target Characteristics: Companies that are not 100% subordinate to a specific single foundation and possess a relatively diversified customer (hospital) portfolio.
  • In particular, mid-to-large regional hub distributors that have internalized basic ERP/WMS infrastructure for inventory/order management and possess their own core logistics warehouse (Hub) facilities, rather than outsourced warehouses.
  • Revenue Size: Companies with KRW 100+ billion in annual revenue and generating stable Operating Cash Flow (OCF).
  • Acquisition Purpose: Eliminates the risk of building a logistics network from scratch and serves as a control tower to absorb the impending flood of bolt-on targets into the system to streamline logistics.
  • Tier 2: Completing Economies of Scale, Bolt-on Targets
  • Target Characteristics: Pure captive distributors owned by hospital directors’ families or foundations that are directly hit by the sledgehammer of this Medical Device Act amendment.
  • They collect intermediary distribution margins relying solely on supply rights based on affiliated relationships, without their own logistics warehouses or advanced IT systems.
  • Revenue Size: Small-scale assets with annual revenues in the KRW 30 billion to KRW 100 billion range.
  • Acquisition Logic and Value Creation (Multiple Arbitrage)
  • Bargain Purchasing: Because they lack substantial logistics fundamentals and are forced sellers who must exit quickly due to regulatory risks, downward valuation pressure is maximized, allowing for acquisition at very low multiples.
  • PMI and Margin Improvement: After acquiring them at a bargain, we simply need to plug the supply volume of these hospitals into the central logistics network and IT system of the Anchor Target built in Tier 1.
  • Since the previously wasted redundant SG&A expenses and affiliated party salaries are normalized, this can generate an increase in operating margin and Multiple Expansion.

Leave a Comment